Corporate ProfileOncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.
February 06, 2017
Oncobiologics Announces Term Extension of Series A Warrantsmore >
January 10, 2017
Oncobiologics Issues Remaining Senior Secured Notes and Warrants – Raising an Aggregate $10.0 Millionmore >
December 23, 2016